Member Posts > Cardiol Therapeutics' CRD-38 - A Breakthrough in Subcutaneous Cannabidiol Therapy for Heart Failure
Revolutionizing Heart Failure Treatment with CRD-38
Cardiol Therapeutics is at the forefront of cardiovascular innovation with CRD-38, a subcutaneous cannabidiol (CBD) formulation developed to enhance heart failure treatment. By leveraging subcutaneous delivery, CRD-38 aims to improve drug absorption, extend dosing intervals, and maximize therapeutic outcomes.
Why Subcutaneous Administration Matters
✔ Enhanced bioavailability, ensuring efficient drug absorption.
✔ Stable plasma concentrations, reducing variability in therapeutic response.
✔ Less frequent dosing, improving patient adherence and convenience.
Scientific Validation of CRD-38
📌 Lower BNP levels, indicating improved cardiac function.
📌 Reduced fat accumulation in cardiac tissue, alleviating stress on the heart.
📌 Strong anti-inflammatory effects, reinforcing CRD-38's disease-modifying potential.
Advancing CRD-38 Toward Clinical Trials
Cardiol Therapeutics is advancing IND-enabling studies to:
✔ Optimize pharmacokinetics for ideal dosing regimens.
✔ Conduct preclinical safety testing to meet regulatory requirements.
✔ Prepare for first-in-human trials to assess efficacy and safety.
🔗 Follow CRD-38's Progress:

#HeartHealth #CardiolTherapeutics #MedicalBreakthrough #CRD38 #CardiacCare #CardiolRx